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Abstract
Background: Chronic obstructive pulmonary disease (COPD) affects independence and survival in the general 
population, but it is unknown to which extent this conclusion applies to elderly people with mild disease. The aim of 
this study was to verify whether mild COPD, defined according to different classification systems (ATS/ERS, BTS, GOLD) 
impacts independence and survival in elderly (aged 65 to 74 years) or very elderly (aged 75 years or older) patients.
Methods: We used data coming from the Respiratory Health in the Elderly (Salute Respiratoria nell'Anziano, SaRA) 
study and compared the differences between the classification systems with regards to personal capabilities and 5-
years survival, focusing on the mild stage of COPD.
Results: We analyzed data from 1,159 patients (49% women) with a mean age of 73.2 years (SD: 6.1). One third of 
participants were 75 years or older. Mild COPD, whichever was its definition, was not associated with worse personal 
capabilities or increased mortality after adjustment for potential confounders in both age groups.
Conclusions: Mild COPD may not affect survival or personal independence of patients over 65 years of age if the 
reference group consists of patients with a comparable burden of non respiratory diseases. Comorbidity and age itself 
likely are main determinants of both outcomes.
Background
Chronic obstructive lung disease has as key feature the
reduction of forced expiratory volume in 1 second (FEV1)
relative to the vital capacity (VC) or to the forced vital
capacity (FVC), and various cut-off of the FEV1/FVC
r a t i o  h a v e  b e e n  p r o p o s e d  t o  d i a g n o s e  t h i s  d i s e a s e .
According to the British Thoracic Society and the UK
National Institute for Clinical Excellence (NICE) a diag-
nosis of COPD requires both FEV1/FVC < 0.7 and FEV1
< 80% predicted [1], while the Global initiative for
Obstructive Lung Disease (GOLD) guidelines proposes a
FEV1/FVC  <0.7 as diagnostic standard, classifying as
GOLD class II those also having a FEV1 < 80% predicted.
The 2004 European Respiratory Society (ERS)/American
Thoracic Society (ATS) guidelines also use a fixed cut-off
of 0.7 for the FEV1/VC ratio [2], but a statement on inter-
pretation of spirometry issued in 2005 strongly suggests
to use the lower limit of normal (LLN) to make a diagno-
sis of bronchial obstruction [3]. In the same guidelines,
severity classification is based on FEV1% predicted, with
a cut-off for the first (mild) class set at 70%.
Further classification issues arise in elderly patients: in
this population the use of the 0.7 fixed cut-off to diagnose
bronchial obstruction has been criticized because it over-
estimates disease prevalence compared to the LLN [4],
and a lower cut-off (0.65) has been proposed [5]. Data
f r o m  t h e  C a r d i o v a s c u l a r  H e a l t h  S t u d y ,  h o w e v e r ,  s h o w
that elderly people with FEV1/FVC < 0.7 but >LLN have
an increased risk of death compared to their counterpart
with FEV1/FVC ≥ 0.7, lending support to the use of a
fixed cut-off set at 0.7 in this population [6].
Data on the prognostic significance of the different
classification methods are scant, especially with respect
to the "mild" category. The interest in the "mild" category
comes also from the fact that two out of the three most
commonly used guidelines include in this classification
patients with a normal FEV1. Since the FEV1 is the physi-
ologic parameter of interest in COPD and it has been
shown to have important prognostic implications [7], it is
reasonable to question what is the prognosis of people
classified as having mild obstruction according to the
ATS/ERS or GOLD classification (i.e. with normal FEV1)
compared to those classified as having mild obstruction
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according to the BTS classification (i.e. with reduced
FEV1). On this basis, we analyzed data coming from a
large collaborative study on respiratory health in elderly
people (SaRA St udy) to verify t he associa tion between
mild COPD, defined according to different algorithms,
and mortality and functional status in a sample of elderly
(age 65 up to 75 years) and very elderly (age ≥ 75 years)
patients.
Methods
Data source
Between January 1996 and July 1999 a total of 1970 out-
patients were recruited from 24 departments of geriatrics
or respiratory medicine within the context of the SA.R.A.
(Salute Respiratoria nell'Anziano - Respiratory Health in
the Elderly) study. Details on the SA.R.A. project are
available elsewhere [8]. This is a multi-centre Italian proj-
ect, investigating various aspects of chronic airway dis-
eases in the elderly population (age ≥65 years) attending
pulmonary or geriatric outpatient clinics. Researchers
had an extensive training in both respiratory function
study of the elderly and multidimensional geriatric
assessment. Enrolment was on a consecutive basis up to
the achievement of a target number of about 200 COPD
and 200 asthmatic patients. The study also enrolled as a
control group outpatients aged 65 years and over attend-
ing the geriatric clinics for non respiratory conditions,
the most common of which were: hypertension (27.3%),
arthritis (27%), diabetes mellitus (12.7%), coronary artery
disease (11.4%), and cerebrovascular diseases (7%). Data
from individual centres were collected by a coordinating
centre at the Cattedra di Malattie dell'Apparato Respira-
torio of the University of Palermo, which was also
responsible for the quality control, the retrieval and the
final processing of data. The study design was approved
by the Ethical Committees of University of Palermo and
of the participating institutions. Patients gave their writ-
ten consent to participate in the study.
Pulmonary function tests
All the centres were provided with an identical fully com-
puterized water-sealed Stead-Wells spirometer (Baires
System; Biomedin; Padua, Italy) matching the standards
of the American Thoracic Society recommendations for
diagnostic spirometry. Baseline and post-bronchodilator
spirometry were performed according to the guidelines of
the American Thoracic Society [9]. All the centers
achieved a high quality performance in spirometry. Spiro-
metric flow-volume curves were considered acceptable if
they had Extrapolated Volume (VEXT) <5% of the FVC
or <0.150 L, a FET >6 sec and a plateau of 1 second, or a
FET >10 sec. According to recommendations by ATS, we
did not exclude curves which did not satisfy the repeat-
ability criteria to avoid the exclusion of data in which an
abnormal lung function causes a greater coefficient of
variation than in normal subjects. Overall, 1,759 spirom-
etries were available for the analysis. Reasons for not per-
forming the exam included refusal, physical impairment,
and inability to understand the instructions.
Sample selection and follow-up
We excluded participants with spirometries that did not
meet acceptability criteria (N = 382). We also excluded
participants with missing anthropometric values (N = 8).
Vital status information as of January 30, 2002 was ascer-
tained by contacting the registry office of the last munici-
pality of residence, and the data was obtained for 1159/
1369 participants (85%). Follow-up time was calculated
from the date of recruitment (first visit) until the date of
death, January 30, 2002, or at 60 months of follow-up,
whichever came first.
Analytic approach
We used three definitions of mild bronchial obstruction
based on current guidelines:
1. FEV1/FVC <LLN; FEV1 >70% predicted (ATS/
ERS)
2. FEV1/FVC <0.7; FEV1 between 50% and 80% pre-
dicted (BTS/NICE)
3. FEV1/FVC <0.7; FEV1 ≥ 80% predicted (GOLD)
Participants could of course fall into more than one def-
inition, and were counted into each.
Thus, the study population consisted of patients meet-
ing at least one of the three definitions of bronchial
obstruction, while the control population included ambu-
latory patients without respiratory problems. Accord-
ingly, we evaluated the prognostic significance of mild
COPD against a control group representative of the gen-
eral elderly population. We used descriptive statistics to
report the demographic and clinical characteristics of the
three groups of patients with mild COPD. Performance
capacity was evaluated using the distance walked in 6
minutes (6MWD), expressed as % of predicted according
to the equation proposed by Enright [10]. Cognition and
mood status were explored using the Mini-mental State
Examination (MMSE) and the Geriatric Depres-sione
Scale (GDS), respectively, while as a reference indicator of
prognosis we used a validated score based on body mass
index, severity of bronchial obstruction, dyspnea, and
exercise capacity (BODE index) [7].
We calculated mortality rated normalized to 100 per-
son/year (100 PY) along with 95% confidence intervals
(95% CI). For each definition, we calculated the mortality
rate ratio using as control group participants who were
non-obstructed according to the relevant classification.
We also obtained an estimate of the hazard ratio for mor-
tality adjusted for age, gender, smoking status and FVC
using a Poisson model. We used this parametric approachPedone et al. BMC Pulmonary Medicine 2010, 10:35
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instead of the more commonly used Cox model because
preliminary analyses showed that the proportional haz-
ard assumption was not tenable.
In order to assess the impact of mild COPD on health
status, we compared the 6MWD, Barthel index, MMSE,
and GDS of control subjects and COPD patients alterna-
tively grouped according to each of the three classifica-
tions. We used ANOVA for data having normal
distribution and homogenous variance, the Kruskal-Wal-
lis test otherwise.
All analyses were performed separately in participants
aged <75 and ≥ 75 years using SAS 9.0 for Windows (SAS
Inc, Cary NC) and Stata 10.0 for Windows (StataCorp,
College Station TX).
Results
Characteristics of the sample
The final sample size was 1,159, women were 48.7%, the
mean age was 73.2 (SD: 6.1), and 429 participants (37.1%)
were 75 years or older. The overall prevalence of bron-
chial obstruction was 40.0%, 28.5%, and 43.6% according
to the ATS/ERS, BTS and GOLD definitions, respectively.
Table 1 shows the prevalence of bronchial obstruction
according to the different definitions. Among partici-
pants aged 65 to 75 years, mild obstruction was present in
18.8%, 18.5%, and 10.8% using the ATS/ERS, BTS, and
GOLD classification, respectively. The prevalence of mild
obstruction among older participants was similar using
the ATS/ERS and BTS classifications, while using the
GOLD definition the figure was doubled (22.4%) com-
pared to the one observed in the group aged 65-75 years.
There were few differences in the prevalence of major
diseases across COPD severity regardless of the classifi-
cation systems; however in patients under 75 years the
BTS-rated mild COPD was associated with a greater
prevalence of ischemic heart disease with regard to non
obstructed patients, while the opposite was true for the
GOLD-rated mild COPD. Also indexes of personal capa-
bilities, cognitive and affective status of controls and
cases alternatively classified according to each of the
three classifications showed no clinically significant dif-
ferences between people without obstruction and with
mild obstruction (tables 2 and 3).
Mortality data in younger participants
In this group, the overall mortality was 2.5/100 person/
year (95% CI: 1.98 - 3.08), with substantial difference
between men (MR: 3.6/100 PY, 95% CI: 2.72 - 4.62) and
women (MR: 1.4/100 PY, 95% CI: 0.94 - 1.14). The most
common causes of death were tumors and cardio-vascu-
lar diseases; pulmonary diseases accounted for 6% of
cases. Moderate/severe obstruction was associated with
an about four-fold mortality regardless of the classifica-
tion system (table 4 and figure 1). Mortality associated
w i t h  m i l d  o b s t r u c t i o n ,  h o w e v e r ,  s h o w e d  d i f f e r e n c e s
according to different definitions: mortality was
increased (MRR: 3.62, 95% CI: 2.14 - 6.07) using the BTS
and, less markedly (MRR 1.97; 95% CI: 1.01 - 3.70), the
ATS classification, while we found no increase in mortal-
ity associated with mild obstruction defined according to
the GOLD criteria (MRR: 1.42, 95% CI: 0.52 - 3.34). After
adjustment for age, gender, smoking exposure and FVC,
the MRR for mortality associated with BTS-rated mild
obstruction was no more statistically significant, while
those associated with more severe obstruction were
reduced, but still statistically significant.
Table 1: Prevalence of bronchial obstruction according to different classification systems, by age
Age 65 - 74 years
N (%)
Age ≥ 75 years
N (%)
ATS/ERS
No obstruction 451 (61.8) 245 (57.1)
Mild obstruction 137 (18.8) 93 (21.7)
Moderate/severe obstruction 142 (19.4) 91 (21.1)
BTS
No obstruction 527 (72.2) 302 (70.4)
Mild obstruction 135 (18.5) 96 (22.4)
Moderate/severe obstruction 68 (9.3) 31 (7.2)
GOLD
No obstruction 448 (61.4) 206 (48.0)
Mild obstruction 79 (10.8) 96 (22.4)
Moderate/severe obstruction 203 (27.8) 127 (29.6)Pedone et al. BMC Pulmonary Medicine 2010, 10:35
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Table 2: Clinical and functional characteristics, by age and severity of obstruction. 
ATS/ERS stage
No Obstruction Mild obstruction Moderate/Severe obstruction
Males (%) 41.2 59.8 68.3
Ischemic heart disease (%) 13.0 13.2 19.9
Cerebro-vascular disease (%) 4.5 3.7 6.4
Diabetes (%) 11.7 9.6 12.1
Cancer (%) 4.0 3.7 4.3
6MWD % predicted (mean [SD]) 81.0 (26.3) 78.2 (24.0) 68.6 (24.2)
GDS score (mean [SD]) 3.5 (3.3) 2.8 (3.1)1 3.7 (3.3)
MMSE score (mean [SD]) 27.7 (3.0) 27.4 (2.8) 26.7 (4.2)
Barthel Index (mean [SD]) 95.0 (7.9) 95.8 (5.0)1 92.8 (7.6)
BTS stage
No Obstruction Mild obstruction Moderate/Severe obstruction
Males (%) 43.3 63.0 76.5
Ischemic heart disease (%) 12.4 22.0 14.7
Cerebro-vascular disease (%) 4.4 5.3 11.8
Diabetes (%) 10.9 12.1 13.2
Cancer (%) 3.8 6.1 1.5
6MWD % predicted (mean [SD]) 80.6 (26.2) 76.3 (21.7) 62.8 (25.3)
GDS score (mean [SD]) 3.5 (3.3) 3.2 (3.2) 3.5 (3.0)
MMSE score (mean [SD]) 27.7 (2.9) 26.9 (3.9)1 26.8 (4.2)
Barthel Index (mean [SD]) 96 (7.7) 95.2 (4.8) 91.5 (8.5)
GOLD stage
No Obstruction Mild obstruction Moderate/Severe obstruction
Males (%) 40.4 59.5 67.5
Ischemic heart disease (%) 13.5 6.4 19.5
Cerebro-vascular disease (%) 4.5 3.8 5.5
Diabetes (%) 11.7 6.4 12.5
Cancer (%) 4.0 2.6 4.5
6MWD % predicted (mean [SD]) 81.3 (26.2) 77.5 (26.0) 71.1 (23.9)
GDS score (mean [SD]) 3.6 (3.3) 2.9 (3.3)1 3.3 (3.2)
MMSE score (mean [SD]) 27.7 (3.0) 27.7 (2.6) 26.8 (4.0)
Barthel Index (mean [SD]) 94.9 (8.0) 95.8 (5.7)1 94.0 (6.5)
Age <75 years.
1P < 0.05.Pedone et al. BMC Pulmonary Medicine 2010, 10:35
http://www.biomedcentral.com/1471-2466/10/35
Page 5 of 9
Table 3: Clinical and functional characteristics, by age and severity of obstruction. 
ATS/ERS stage
No Obstruction Mild obstruction Moderate/Severe obstruction
Males (%) 47.3 58.1 65.9
Ischemic heart disease (%)1 21.6 23.1 25.6
Cerebro-vascular disease (%) 11.0 5.6 4.4
Diabetes (%) 15.9 15.4 16.7
Cancer (%) 8.2 8.8 4.4
6MWD % predicted (mean [SD]) 76.8 (30.5) 78.1 (24.7) 66.2 (24.9)
GDS score (mean [SD]) 4.2 (3.3) 3.6 (3.4) 4.5 (3.5)
MMSE score (mean [SD]) 26.5 (3.7) 26.4 (4.2) 25.3 (4.8)
Barthel Index (mean [SD]) 92.8 (9.6) 92.6 (12.4) 91.0 (10.9)
BTS stage
No Obstruction Mild obstruction Moderate/Severe obstruction
Males (%) 47.3 66.7 74.2
Ischemic heart disease (%)1 21.9 24.5 25.8
Cerebro-vascular disease (%) 10.0 5.3 3.2
Diabetes (%) 16.6 16.0 9.7
Cancer (%) 8.3 6.4 3.2
6MWD % predicted (mean [SD]) 78.9 (29.0) 69.9 (24.0)1 57.8 (26.8)
GDS score (mean [SD]) 4.0 (3.3) 4.2 (3.5) 5.2 (4.1)
MMSE score (mean [SD]) 26.5 (3.8) 25.6 (4.6)1 25.6 (4.5)
Barthel Index (mean [SD]) 92.9 (10.3) 91.7 (9.9) 89.7 (14.1)
GOLD stage
No Obstruction Mild obstruction Moderate/Severe obstruction
Males (%) 42.7 57.3 68.5
Ischemic heart disease (%)1 22.3 21.0 24.8
Cerebro-vascular disease (%) 11.2 7.4 4.8
Diabetes (%) 16.5 16.8 14.4
Cancer (%) 7.8 9.5 5.6
6MWD % predicted (mean [SD]) 81.3 (29.4) 75.2 (28.0) 66.8 (25.1)
GDS score (mean [SD]) 4.1 (3.6) 3.6 (3.3) 4.4 (3.7)
MMSE score (mean [SD]) 26.7 (3.6) 26.1 (4.3) 25.6 (4.5)
Barthel Index (mean [SD]) 93.3 (9.3) 92.1 (12.2) 91.2 (11.0)
Age ≥ 75 years.
1P < 0.05.Pedone et al. BMC Pulmonary Medicine 2010, 10:35
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Mortality data in older participants
As expected, the overall mortality of older participants
was higher, 6.9/100 person/year (95% CI: 5.68 - 8.28).
Once again, mortality was higher in men (MR: 8.7/100
PY, 95% CI: 6.95 - 10.88) compared to women (MR: 5.0/
100 PY, 95% CI: 3.67 - 6.77). The most common cause of
death were cardio-vascular diseases (31.7%) and tumors
(25.2%); pulmonary diseases accounted for 13.0% of
deaths. Only mild obstruction defined according to the
BTS criteria was associated with increased mortality
(table 4 and figure 2) in this group. More severe obstruc-
t i o n  w a s  a s s o c i a t e d  w i t h  m o r t a l i t y ,  b u t  t h e  r i s k  w a s
increased less compared to patients aged 65-75 years;
severe obstruction defined according to the BTS criteria
was associated with the greatest increase in risk (MRR:
2.83, 95% CI: 1.43 - 5.60). After correction for potential
confounders, only severe COPD as defined by the BTS
criteria was still associated with mortality (MRR: 2.01;
95% CI: 1.07 - 3.98). Since in older patients mortality
associated with COPD might be reduced because of com-
peting risk, we evaluated whether another severity indi-
cator (the BODE index) was associated with mortality in
this age group and found an adjusted HR of 1.26 (95% CI:
1.14 - 1.41) for each one-point increase in the BODE
score.
Discussion
Our results confirm that the estimated prevalence of
COPD depends on the definition used, but "mild" COPD,
regardless of the definition used, impacts neither progno-
sis nor personal capabilities in an elderly population.
Clinical diagnosis of COPD should not rely on spirome-
try alone, but a positive spirometry is required by all
guidelines to make a definitive diagnosis. For this reason,
and also for practicality, most epidemiological studies use
s p i r o m e t ry  t o  i d e n t i fy  pe o p l e  w i t h  C O P D ,  m a k i n g  t h e
issue of spirometric definition of bronchial obstruction
an important one. As expected, the GOLD guidelines
yielded the highest estimated prevalence of COPD and
the BTS the lowest, a result that is also in line with other
studies [11,12]. Diagnostic algorithms using a fixed cut-
off to identify bronchial obstruction are expected to pro-
vide higher prevalence estimates in the elderly compared
to algorithms using the LLN; in our data, however, this
was true for the GOLD but not for the BTS classification.
The likely explanation for this finding is that the BTS
classification system also requires a reduction of the
FEV1%. On the other hand, it cannot be excluded that the
prevalence of COPD in elderly people is actually higher,
as shown by different authors [13,14]. It should be noted,
however, that most of these data have been obtained in
studies defining COPD using a fixed cut-off, and no data
are available on the age-specific prevalence of COPD
defined using the LLN.
The use of the LLN is only partial solution to these
problems. The LLN is population-specific, and ideally
should be calculated on a subset of healthy, non-smoking
persons of the population under study, which is obviously
hardly feasible in most studies and in the clinical setting.
Using LLN derived from external studies is easier, but
they can have a wide variability [15] and their use also
carries a significant risk of misclassification [16,17].
Table 4: Crude and adjusted mortality rate ratios (MRR) associated with severity of obstruction according to different classification 
systems, by age.
Crude MRR Adjusted1 MRR
Age < 75 years Age ≥ 75 years Age < 75 years Age ≥ 75 years
ATS
Mild obstruction 1.97 (1.01-3.70) 0.75 (0.43-1.25) 1.70 (0.92-3.18) 0.80 (0.48-1.33)
Moderate/severe obstruction 4.62 (2.78-7.76) 1.71 (1.11-2.58) 2.64 (1.49-4.68) 1.31 (0.83-2.10)
BTS
Mild obstruction 3.62 (2.14-6.07) 2.52 (1.50-4.25) 1.28 (0.80-1.98) 1.05 (0.66-1.68)
Moderate/severe obstruction 4.68 (2.53-8.41) 2.83 (1.43-5.60) 3.03 (1.73-5.06) 2.01 (1.07-3.98)
GOLD
Mild obstruction 1.42 (0.52-3.34) 0.97 (0.57-1.50) 1.21 (0.51-2.87) 0.98 (0.60-1.61)
Moderate/severe obstruction 4.22 (2.60-6.98) 1.64 (1.09-2.47) 2.67 (1.60-4.48) 1.19 (0.77-1.85)
1Adjusted for age, gender, smoking exposure, and FVC.Pedone et al. BMC Pulmonary Medicine 2010, 10:35
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In participants aged 65-75 years, we have found that,
after adjustment for potential confounders, mild COPD is
not associated with increased mortality, but this finding
should be interpreted also taking into account the rela-
tively small sample size of our study. Mannino et al. have
shown in a population aged up to 66 years that the
adjusted hazard ratio for mortality in GOLD stage 1
COPD was 1.4 (95% CI: 1.1 - 1.6), which is close to the 1.2
we found in our sample [18]. In another large screening
study, among middle-aged men the hazard ratio for mor-
tality associated with GOLD 1 ranged from 0.8 to 1.3,
depending on smoking exposure [19]. There are scant
data on the risk of mortality in patients with mild COPD
as defined by the ATS/ERS criteria; it has been shown,
however, that people aged 65 years and older with FEV1/
FVC  <LLN and FEV1 ≤ 80% of predicted have an
adjusted mortality rate ratio of 1.4 [6].
Interestingly, in the group aged 75 years and older, we
found no association between moderate/severe COPD
(ATS/ERS and GOLD classification) and mortality. This
finding likely reflects the preeminent prognostic role of
non respiratory factors in older people, even with
severely reduced FEV1. Among these factors are age
itself, comorbidity and performance capacity [20].
Indeed, we found that the BODE Index was associated
Figure 1 Survival by COPD severity in patients aged 65-74 years 
(unadjusted Kaplan-Meier curves). Upper panel: ATS/ERS classifica-
tion; middle panel: BTS classification; lower panel: GOLD classification. 
Log-rank P < 0.001.
Figure 2 Mortality by COPD severity in patients aged ≥ 75 years 
(unadjusted Kaplan-Meier curves). Upper panel: ATS/ERS classifica-
tion; middle panel: BTS classification; lower panel: GOLD classification. 
Log-rank P = 0.003.Pedone et al. BMC Pulmonary Medicine 2010, 10:35
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with mortality in this age group, indicating that a multidi-
mensional index is effective also for the very old. Further
supporting the primary role of multidimensional assess-
ment in contrast to the monodimensional FEV1-based
assessment is the finding that people with respiratory
symptoms, but without spirometric abnormalities, have a
worse prognosis [18,19]. Furthermore, symptomatic, but
not asymptomatic, patients with GOLD stage 1 COPD
have faster FEV1 decline, increased respiratory care utili-
zation, and worse quality of live [21]. Even in GOLD
stages 2-3, symptoms seem to have important prognostic
implication over and above spirometric abnormalities
[19]. Thus, the global burden of disease rather than bron-
chial obstruction seems relevant to predict prognosis of
elderly COPD patients. At any rate, it should be noted
that the relationship between FEV1 reduction and mor-
tality is a complex one, as shown by recent randomized
trials showing that improvement in FEV1 does not trans-
late in increased survival [22,23].
In this sample, personal capabilities, affective and cog-
nitive status of mild COPD patients did not differ from
those of control subjects with comparable non respira-
tory diseases, indicating that comorbidity, more than
mild COPD, likely accounts for impaired health status. A
study by Coultas et al. [24], however, have found impaired
personal capabilities even in COPD subjects unaware of
h a v i n g  t h e  d i s e a s e ,  w h i c h  i s  c o n s i s t e n t  w i t h  a n  d i r e c t
association between mild COPD and health status. Dif-
ferences in mean age between ours (73.2 years) and Coul-
tas' patients (65.7 years) might explain this discrepancy.
Furthermore, our controls were not healthy subjects, but
patients with non respiratory conditions. This likely
enabled us to disclose the relationship between comor-
bidity and personal capabilities.
Finally, physical performance measured by the 6MWD
was not different between participants with mild COPD
defined by the three alternative classifications, although
those diagnosed according to the BTS criteria have a
lower FEV1. This is confirmatory of previous studies
showing that the FEV1 is not the best predictor of perfor-
mance capacity in COPD [25,26] and that patients with
mild disease defined using the GOLD criteria have a per-
formance similar to that of a control group free from pul-
monary diseases [27].
This study is limited by its relatively low power and by
the fact that its 5 years follow-up time may be too short to
detect important differences in mortality in people hav-
ing mild COPD. It should be noted, however, that the
mean age of our older participants -- which was the
group of major interest -- was 80 years, and in a group
with such an age five years should suffice to provide
information on mortality. It should be also noted that the
selection of patients from health care facilities might limit
the representativeness of the sample. Furthermore, we
had no generic index of health-related quality of life
recorded in the whole population and we cannot exclude
that mild COPD affects this outcome. On the other hand,
the availability of a control group with comparable age
and comorbidity improves the reliability of our estimates
of the prognostic properties of mild COPD. Finally, a con-
sistent proportion of participants could not perform an
acceptable spirometry. This information is not new, and
we have already reported [8] that elderly patients unable
perform an acceptable spirometry have worse physical
and cognitive performance, and lower education and
therefore have an inherently poorer prognosis. In theory,
obtaining acceptable spirometric information also in
these patients (e.g. using the FEV6 instead of the FVC)
might show a poorer prognosis even in those with mild
obstruction.
Conclusions
Our data indicate that mild COPD may not affect survival
and personal capabilities of patients over 65 years,
regardless of the criteria used to diagnose it. In this group
of patients, comorbidity and age itself likely are the major
determinants of these outcomes.
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